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richesd@njhealth.org.Idiopathic pulmonary ﬁbrosis (IPF) is a progressive and
usually fatal ﬁbrotic disease of the distal lung alveolar gas
exchange units.1 IPF is typically diagnosed in older
individuals, after the disease is well established. IPF patients
experience progressive shortness of breath, reduced quality
of life, and a median survival of only 2 to 3 years after
diagnosis.2 The disease burden is signiﬁcant considering that
the prevalence of disease in the United States is estimated to
be between 14 and 42.7 cases per 100,000 individuals3 and
rising.4 Until the recent US Food and Drug Administration
approval of pirfenidone and nintedanib, there were no
effective therapies.5,6 However, despite these recent break-
throughs, the outlook for IPF patients remains bleak, and
there continues to be an urgent need for new therapies to
impede disease progression and, more desirably, reverse
established ﬁbrosis.
IPF is thought to develop in response to extensive and
repetitive injury to the alveolar epithelial cells, resulting
in apoptosis and the development of an abnormal repair
response.7 As is typical of wound repair in other sites,
such as the skin, resident ﬁbroblasts and myoﬁbroblast
progenitors proliferate and migrate to the injured lung
parenchyma. In the transforming growth factor (TGF)-
berich proﬁbrotic microenvironment of the alveoli and
interstitium, ﬁbroblasts and myoﬁbroblast progenitors
express contractile proteins, such as a smooth muscle
actin (a-SMA), ramp up production of extracellular
matrix (ECM) proteins,8,9 and acquire a canonical myo-
ﬁbroblast phenotype. However, unlike normal resolving
wound repair, in which myoﬁbroblasts contract the
newly synthesized provisional matrix, undergo apoptosis,Copyright ª 2015 American Society for Investigative Pathology.
Published by Elsevier Inc. All rights reserved.
http://dx.doi.org/10.1016/j.ajpath.2015.01.005and are cleared from the wound once repair is complete,
lung myoﬁbroblasts develop resistance to apoptosis
induction, continue to produce excessive amounts of
ﬁbrotic ECM, and maintain their contractile properties in
the lungs of IPF patients.10 Thus, a full understanding
of the molecular mechanisms that control ﬁbroblaste
myoﬁbroblast differentiation and their acquired resistance
to apoptosis is essential to develop therapeutic approaches
to reduce lung myoﬁbroblast numbers, excessive ECM
production, and tissue contraction in IPF patients.
Activation of Myoﬁbroblasts in Fibrosis and
the Role of ROCK Signaling
Studies reported by Sisson et al11 in this issue of The
American Journal of Pathology expand current insights
into the mechanisms that control ﬁbroblastemyoﬁbroblast
differentiation and their resistance to apoptosis induction
in IPF. As illustrated in Figure 1, ﬁbroblastemyoﬁbroblast
differentiation can be initiated by a cadre of quintessential
Figure 1 Fibroblastemyoﬁbroblast differenti-
ation is initiated by environmental factors, such as
transforming growth factor (TGF)-b, lysophospha-
tidic acid (LPA), and mechanotransduction, and is
mediated via the Rho-ROCKemyocardin-related
transcription factor (MRTF) signaling pathway.
These initial signaling events result in the poly-
merization of G-actin to F-actin and the formation
of contractile ﬁbers, a characteristic of myoﬁbro-
blasts. Polymerization of F-actin frees the tran-
scription factor MRTF, normally sequestered in the
cytoplasm by association with G-actin, to trans-
locate to the nucleus, initiating transcription of
several proﬁbrotic and antiapoptotic genes. CCG-
203971 exerts its antiﬁbrotic effect by inhibiting
MRTF nuclear translocation, thereby preventing the
up-regulation of gene expression. a-SMA, a smooth
muscle actin; Bcl-2, B cell lymphoma 2; FN, ﬁbro-
nectin; PAI-1, plasminogen activator inhibitor-1;
SRF, serum response factor; XIAP, X-linked inhibitor
of apotosis.
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acid, thrombin, plasminogen activator inhibitor-1, and
mechanotransductive sensing of the increasing stiffness
of ﬁbrotic ECM.12,13 Many of these molecules initiate
ﬁbroblastemyoﬁbroblast differentiation by stimulating
GTP loading of Rho family GTPases, especially RhoA,
which activates the downstream Rho-associated coiled-
coil-containing protein kinases (ROCK)-1 and -2.14 These
homologous serine/threonine kinases phosphorylate mul-
tiple downstream substrates, including myosin light-chain
phosphatase, that permit myosin light-chain phosphoryla-
tion, facilitating the polymerization of globular G-actin
into ﬁlamentous F-actin and initiating the assembly of the
actomyosin contractile machinery.
Myocardin-related transcription factors (MRTFs) A and
B (alias megakaryoblastic leukemia factors 1 and 2) are
transcriptional coactivators that, when constitutively
bound to G-actin, remain sequestered in the cytoplasm and
transcriptionally inactive. During ROCK-1/2edependent
F-actin assembly, MRTFs dissociate from G-actin, trans-
locate to the nucleus, and coactivate serum response
factoremediated transcription of ﬁbronectin, procollagen
1, and other ECM genes.15 Nuclear translocation of MRTF-
A also promotes the expression of a-SMA and anti-
apoptotic proteins B cell lymphoma 2 (Bcl-2) and X-linked
inhibitor of apotosis (XIAP), thereby enhancing contractile
potential and promoting myoﬁbroblast resistance to
apoptosis.16 In vivo studies in a mouse model of pulmonary
ﬁbrosis have validated the importance of these collective
ﬁndings by showing that the development of pulmonary
ﬁbrosis is impaired in mice that have been prophylactically
treated with the ROCK inhibitors Y27632 or fasudil before
bleomycin instillation.16e18 The development of pulmo-
nary ﬁbrosis is also impaired in MRTF-deﬁcient mice.16
Thus, components of the Rho-ROCK-MRTF signaling
pathway are legitimate therapeutic targets that, when910blocked, inhibit the development of pulmonary ﬁbrosis and
accelerate its resolution.In Vivo Blockade of MRTF-A Signaling Reduces
Pulmonary Fibrosis
Sisson et al11 build on the concept of therapeutically tar-
geting the Rho-ROCK-MRTF signaling pathway to treat
ﬁbrotic lung disease. After its release from G-actin during
ROCK-1/2edependent F-actin assembly, MRTF-A is trans-
located from the cytoplasm into the nucleus through the
activity of the importin nuclear translocator.19 Sisson et al11
hypothesized that reducing nuclear import of MRTF-A
would impair the expression of several proﬁbrotic and
antiapoptotic genes that are involved in the development
and maintenance of ﬁbrosis. Using a high-throughput
screen to discover candidate small molecule inhibitors
of serum response factor/MRTF transcriptional activity,
they identiﬁed CCG-203971. Their initial studies showed
that CCG-203971 reduced TGF-beinduced MRTF-A
nuclear translocation and suppressed TGF-beinduced
expression of a-SMA and ﬁbronectin in human ﬁbroblast
cell lines. These ﬁndings provided impetus to determine
the effect of CCG-203971 in experimental models of
pulmonary ﬁbrosis in mice.
Intratracheal instillation of bleomycin has been widely used
to study the mechanisms involved in the development of pul-
monary ﬁbrosis. The bleomycin model is characterized by an
initial inﬂammatory acute lung injury peaking at day 7 and
associated with extensive alveolar epithelial cell apoptosis. This
phase is then replaced by a postinﬂammatory ﬁbrotic phase,
peaking at 14 to 21 days, and associated with ﬁbroblaste
myoﬁbroblast differentiation and the expression of increased
proﬁbrotic gene signatures. Sisson et al11 investigated the effect
of CCG-203971 on the ﬁbrotic phase by initiating treatmentajp.amjpathol.org - The American Journal of Pathology
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reduced the amount of lung ﬁbrosis at day 21 and resulted in an
improvement in lung architecture, indicating resolution of pre-
existing ﬁbrosis. They also tested CCG-203971 in a second
ﬁbrotic model involving targeted induction of apoptosis in
alveolar type II cells that results in mild ﬁbrosis lacking the
characteristic inﬂammatory response of the bleomycin model.
CCG-203971 reduced the ﬁbrotic response in this alternative
model as well, suggesting that the initial ﬁndings in bleomycin-
instilled mice were not model speciﬁc.
To gain further mechanistic insight into the antiﬁbrotic
action of CCG-203971, the number of apoptotic myoﬁbro-
blasts were quantiﬁed by evaluating terminal deoxy-
nucleotidyl transferase dUTP nick end labeling (TUNEL)/
a-SMA double-positive cells in the bleomycin-induced
ﬁbrotic lesions. Consistent with the literature, the ﬁbrotic
lungs of bleomycin-instilled mice contained predictably few
apoptotic myoﬁbroblasts. However, inhibition of MRTF-A
nuclear translocation in CCG-203971etreated ﬁbrotic mice
resulted in increased numbers of TUNEL/a-SMAepositive
myoﬁbroblasts, suggesting that the compound may also be
promoting myoﬁbroblast apoptosis. This result is similar to
observations made after ROCK inhibition with fasudil,16
suggesting a similar mechanism of action in vivo after the
upstream blockade of the Rho-ROCK-MRTF pathway.
Taken together, the in vivo studies reported by Sisson et al11
suggest that inhibition of the nuclear import of the MRTF-A
by CCG-203971 promotes the resolution of established
pulmonary ﬁbrosis, at least in part, by reducing the proﬁ-
brotic phenotype of myoﬁbroblasts and by promoting their
apoptosis.Rho-ROCK-MRTF Signaling during Myoﬁbroblast
Apoptosis
Although little is known about the receptors, ligands, and
other processes that promote ﬁbroblast apoptosis during
the resolution of wound repair in vivo, there are strong
implications that the death receptor Fas may be involved.
Mice with inactivating mutations in FasL have been
observed to develop a mild ﬁbroproliferative interstitial
pneumonia that is similar to some forms of rheumatoid
arthritiseassociated interstitial lung disease.20 Further-
more, lung ﬁbroblasts isolated from the ﬁbrotic lungs of
bleomycin-induced wild-type mice and primary cultures of
lung ﬁbroblasts from IPF patients have uniformly been
found to be resistant to Fas-induced apoptosis.21,22 With
these ﬁndings in mind, Sisson et al11 next investigated the
effect of CCG-203971 on Fas-induced lung ﬁbroblast
apoptosis. The authors had previously shown that ﬁbro-
blasts incubated in the presence of TGF-b were protected
from Fas-induced apoptosis through a mechanism that
involved increased expression of the broad-acting caspase-
inhibitor protein, XIAP.23 In their current studies, Sisson
et al11 found that while treatment with CCG-203971 aloneThe American Journal of Pathology - ajp.amjpathol.orghad no effect on lung ﬁbroblast apoptosis, it sensitized the
cells to Fas-induced apoptosis even in the presence of
TGF-b. The ability of CCG-203971 to sensitize ﬁbroblasts
to Fas-induced apoptosis was similar in normal ﬁbroblasts
and IPF myoﬁbroblasts. Thus, these in vitro studies iden-
tify a potential mechanism to account for the increased
number of apoptotic myoﬁbroblasts in the previously
ﬁbrotic lungs of CCG-203971etreated mice.
In the setting of IPF, the data reported by Sisson et al11
reveal important new insights into the mechanisms con-
trolling lung myoﬁbroblast function and sensitivity to
apoptosis. Inevitably, however, they also raise additional
questions. For example, Sisson et al11 found that blocking
MRTF nuclear translocation with CCG-203971 sensitized
myoﬁbroblasts to apoptosis by reducing cytoplasmic levels
of the intrinsic pan-caspase inhibitor, XIAP. In contrast,
Zhou et al16 found that the mechanism of apoptosis induced
by the ROCK inhibitor fasudil involved down-regulation of
the antiapoptotic protein Bcl-2 in a Fas-independent
manner. Golan-Gerstl et al22 suggested that lung myoﬁ-
broblast resistance to apoptosis is mediated by an additional
antiapoptotic mechanism involving increased c-FLIP
expression. Although it is conceivable that multiple anti-
apoptotic mechanisms may contribute to the resistance of
ﬁbrotic lung myoﬁbroblast to apoptosis, a comprehensive
analysis of these mechanisms remains to be conducted. An
additional issue that deserves attention is the role of the
death receptor Fas in myoﬁbroblast apoptosis. In vitro
studies, including the study by Sisson et al,11 have clearly
shown that Fas ligation plays an important role in pro-
moting the apoptosis of appropriately sensitized primary
lung myoﬁbroblasts. However, little is known about the
physiological mechanisms that promote myoﬁbroblast
apoptosis in vivo or the role of Fas ligand-dependent Fas
ligation in this process. Indeed, although our under-
standing of the mechanisms involved in myoﬁbroblast
accumulation and persistence in IPF has greatly improved
over the past decade, much remains to be determined
about how these cells die and are removed in physiolog-
ical repair processes and in the setting of ﬁbrotic diseases
of the lung and other organs.Therapeutic Potential of the Rho-ROCK-MRTF
Pathway
In summary, the ﬁndings reported in this issue of the AJP by
Sisson et al11 highlight the importance of the Rho-ROCK-
MRTF signaling pathway in maintaining myoﬁbroblast
function in the setting of ﬁbrotic lung disease. Importantly,
they identify CCG-203971, a novel small molecule thera-
peutic inhibitor of MRTF-A nuclear translocation, and show
that it blocks ﬁbroblast-myoﬁbroblast differentiation, sen-
sitizes myoﬁbroblasts to apoptosis, and accelerates the res-
olution of pulmonary ﬁbrosis in mice, thus revealing an
additional and innovative approach to therapeutically target911
Riches et alRho-ROCK-MRTF signaling in IPF. Lastly, and of broader
signiﬁcance, their ﬁndings may be of considerable relevance
to the control of ﬁbrosis in other organs since MRTF-A has
also been implicated in the development of cardiac and renal
ﬁbrosis.24,25
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